Biotech company AnchorDx has formed a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products globally. Based in Guangzhou, China, AnchorDx, and Pleasanton, California-based DiaCarta plan to leverage their proprietary technologies for DNA methylation and mutation detection in this collaboration. The financial and other terms of the partnership were not disclosed.
AnchorDx aims to accelerate its early cancer screening programs and develop a robust product pipeline through this collaboration. The company’s pipeline currently covers over 70% of high-incidence cancers. AnchorDx received breakthrough device designation from the U.S. Food and Drug Administration in 2021 for its UriFind liquid biopsy test for bladder cancer detection. The company is conducting a registrational and prospective clinical trial for this urine-based assay, with DiaCarta serving as one of the clinical testing laboratories for the trial.